-+ 0.00%
-+ 0.00%
-+ 0.00%

Shandong Boan Biotech completes China Phase Ia trial of BA1302 CD228-targeted ADC

PUBT·08/14/2026 14:17:00
Listen to the news
Shandong Boan Biotech completes China Phase Ia trial of BA1302 CD228-targeted ADC
  • Shandong Boan Biotechnology completed China Phase Ia dose-escalation for BA1302, a CD228-targeted antibody-drug conjugate in advanced solid tumors.
  • Results have been presented in the announcement, with early signs of tumor shrinkage in several heavily pretreated cancers.
  • Safety profile appeared manageable, with most treatment-related side effects described as mild to moderate.
  • Next step is a Phase Ib dose-expansion study to test BA1302 in selected tumor types.
  • U.S. FDA cleared a U.S. clinical trial; BA1302 received orphan-drug status for squamous NSCLC, pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260814-12285695), on August 14, 2026, and is solely responsible for the information contained therein.